Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing immunotherapies, has received a milestone payment following dosing the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET.   ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly’s platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter the c...